To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Proteasome inhibitors are drugs that block the action of proteasomes, cellular complexes that break down proteins, like the p53 protein. Proteasome inhibitors are being studied in the treatment of cancer. In 2003, bortezomib was the first proteasome inhibitor to be approved for use in the U.S.
A derivative of epigallocatechin-3-gallate has been proposed as another proteasome inhibitor.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Proteasome_inhibitor". A list of authors is available in Wikipedia.|